GO:0032651 regulation of interleukin-1 beta production: Inflammatory Cytokine Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032651 (regulation of interleukin-1 beta production) is a biological process that modulates the frequency, rate, or extent of interleukin-1 beta (IL-1 beta) production, encompassing biosynthesis and secretion.
• IL-1 beta is a master pro-inflammatory cytokine whose production is tightly controlled; dysregulation contributes to autoinflammatory, metabolic, and neurodegenerative conditions.
• Key regulatory nodes include inflammasome components (NLRP3, caspase-1), oxidative stress pathways, and cytokine-stimulated feedback loops.
• Experimental models such as THP-1, RAW264.7, and primary lymphocytes are widely used to dissect IL-1 beta regulation.
• Defective IL-1 beta production has been observed in type 2 diabetes mellitus and can be restored by glycemic control, highlighting clinical relevance.
• CRISPR-based knockout, knock-in, and overexpression models enable causal interrogation of genes regulating IL-1 beta production.
Description
Interleukin-1 beta (IL-1 beta) is a potent pro-inflammatory cytokine that orchestrates host defense and immune responses. The biological process termed regulation of interleukin-1 beta production (GO:0032651) encompasses any mechanism that modulates the frequency, rate, or extent of IL-1 beta biosynthesis and secretion. This process is critical because excessive or insufficient IL-1 beta production is linked to a wide spectrum of human diseases, including autoinflammatory disorders, diabetes, and cystic fibrosis. Understanding the molecular players that govern IL-1 beta production is therefore essential for both basic immunology and therapeutic development. Research has identified multiple regulatory layers, from inflammasome activation and caspase-1 activity to oxidative stress and cytokine feedback. For example, monosodium urate crystals induce IL-1 beta production in THP-1 cells through oxidative stress and caspase-1, a pathway that can be suppressed by rebamipide. Similarly, tributyltin stimulates IL-1 beta synthesis in human lymphocytes, demonstrating environmental modulation of this process. These findings underscore the complexity of GO:0032651 and the need for robust experimental models to dissect its components.
regulation of interleukin-1 beta production At A Glance
| GO ID | GO:0032651 |
|---|---|
| GO term | regulation of interleukin-1 beta production |
| Ontology | biological_process |
| Synonym | regulation of IL-1 beta production; regulation of interleukin-1 beta biosynthetic process; regulation of interleukin-1 beta secretion |
| Major function | Modulates the frequency, rate, or extent of IL-1 beta production, including biosynthesis and secretion |
| Related cytokines | IL-1 beta (IL1B), IL-6, TNF-alpha |
| Key regulatory nodes | Inflammasome (NLRP3), caspase-1, oxidative stress, TACE/ADAM17 |
| Disease relevance | Autoinflammatory diseases, type 2 diabetes, cystic fibrosis, osteoarthritis, neuroinflammation |
What Is GO:0032651?
According to the Gene Ontology, GO:0032651 (regulation of interleukin-1 beta production) is defined as any process that modulates the frequency, rate, or extent of interleukin-1 beta production. This includes regulation of IL-1 beta biosynthetic process and IL-1 beta secretion. In practice, it covers signaling events, transcriptional and post-transcriptional control, inflammasome activation, and secretory mechanisms that ultimately determine the amount of bioactive IL-1 beta released by cells.
Why Is regulation of interleukin-1 beta production Important in Cell Biology?
Regulation of IL-1 beta production is a central node in inflammatory biology. Because IL-1 beta is a powerful pyrogen and immune amplifier, its production must be tightly controlled; loss of this control drives chronic inflammation and tissue damage. Therapeutic strategies targeting IL-1 beta or its production are already in clinical use for autoinflammatory syndromes, and understanding the regulatory mechanisms can reveal new drug targets. Moreover, conditions such as type 2 diabetes and cystic fibrosis show altered IL-1 beta production, suggesting that modulating this process could have broad clinical benefit.
• IL-1 beta is a key mediator of fever, acute-phase response, and immune cell recruitment.
• Dysregulated IL-1 beta production contributes to autoinflammatory diseases such as cryopyrin-associated periodic syndromes.
• Type 2 diabetes mellitus is associated with defective IL-1 beta production that can be restored by glycemic control.
• Cystic fibrosis airway inflammation involves IL-1 beta as a potential mediator of nitric oxide deficiency.
• IL-1 beta upregulates TACE, which affects APP processing and Abeta production, linking neuroinflammation to Alzheimer's disease.
• Environmental toxicants like tributyltin can stimulate IL-1 beta synthesis in human lymphocytes.
• Monosodium urate crystals, relevant to gout, induce IL-1 beta via oxidative stress and caspase-1.
• MSC exosomes can attenuate inflammation partly by modulating IL-1 beta in osteoarthritis models.
• Apigenin exhibits anti-inflammatory effects by modulating IL-1 beta in RAW264.7 cells.
• Understanding GO:0032651 aids in developing targeted anti-cytokine therapies.
What Happens During regulation of interleukin-1 beta production?
Inflammasome Activation and Caspase-1 Cleavage
In simple terms: The inflammasome is a molecular platform that activates an enzyme called caspase-1, which cuts pro-IL-1 beta into its active form.
A major step in IL-1 beta production is the activation of the NLRP3 inflammasome, which recruits and activates caspase-1. Active caspase-1 cleaves pro-IL-1 beta to generate mature IL-1 beta, a critical regulated step. In THP-1 cells, monosodium urate crystals induce IL-1 beta production through oxidative stress and caspase-1, and this can be suppressed by rebamipide. This highlights the inflammasome-caspase-1 axis as a central regulatory node in GO:0032651.
Transcriptional and Post-transcriptional Control
In simple terms: Cells can increase or decrease the amount of IL-1 beta mRNA and protein by controlling gene transcription and mRNA stability.
The production of IL-1 beta is regulated at the level of gene expression. Pro-inflammatory stimuli such as lipopolysaccharide (LPS) activate NF-kB and other transcription factors that drive IL1B transcription. Additionally, mRNA stability and translation can be modulated. In human lymphocytes, tributyltin stimulates the synthesis of IL-1 beta and IL-6, demonstrating that environmental agents can act at the transcriptional or post-transcriptional level. This layer of regulation ensures that IL-1 beta is produced only when needed.
Oxidative Stress and Redox Regulation
In simple terms: Reactive oxygen species can act as signals that turn on or off IL-1 beta production.
Oxidative stress is a known regulator of IL-1 beta production. In THP-1 cells, monosodium urate crystal-induced IL-1 beta production is mediated by oxidative stress, and antioxidants like rebamipide can suppress it. This indicates that redox balance is an important determinant of GO:0032651. The interplay between reactive oxygen species and inflammasome activation is a subject of active research.
Feedback and Cytokine Networks
In simple terms: IL-1 beta itself can influence other cytokines and be influenced by them, creating feedback loops.
IL-1 beta production is embedded in a network of cytokines. For instance, IL-1 beta upregulates TACE (ADAM17) in neurons, which enhances alpha-cleavage of APP and decreases Abeta production. This shows that IL-1 beta can modulate other proteolytic processes. Additionally, IL-6 is often co-regulated with IL-1 beta, as seen in tributyltin-stimulated lymphocytes. Such crosstalk fine-tunes the inflammatory response.
Secretion and Extracellular Release
In simple terms: After being made, IL-1 beta must be released from the cell to act on others.
IL-1 beta lacks a signal peptide and is secreted via unconventional pathways, including microvesicle shedding and gasdermin D pores. Regulation of secretion is part of GO:0032651, as the synonym 'regulation of interleukin-1 beta secretion' indicates. The exact secretory mechanisms are still being elucidated, but they are critical for the cytokine's biological activity.
Key Genes Involved in GO:0032651 regulation of interleukin-1 beta production
The following genes and proteins are key players in the regulation of IL-1 beta production, based on experimental evidence from the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL1B | Encodes pro-IL-1 beta, the precursor of mature IL-1 beta | Central to all studies of IL-1 beta production; target for knockout and overexpression |
| NLRP3 | Inflammasome sensor that activates caspase-1 | Key regulator; mutations cause autoinflammatory diseases |
| CASP1 | Caspase-1 cleaves pro-IL-1 beta to active form | Essential for maturation; knockout blocks IL-1 beta production |
| ADAM17 | TACE, up-regulated by IL-1 beta, cleaves APP | Links IL-1 beta to neurodegeneration |
| NFKB1 | Transcription factor driving IL1B expression | Master regulator of inflammatory gene transcription |
| IL6 | Cytokine co-regulated with IL-1 beta | Often measured together as inflammatory marker |
| TNF | Pro-inflammatory cytokine that can induce IL-1 beta | Part of cytokine network |
| P2RX7 | ATP receptor that triggers inflammasome activation | Regulates IL-1 beta release in response to danger signals |
| GSDMD | Forms pores for IL-1 beta secretion | Mediates unconventional secretion |
| TLR4 | Recognizes LPS and initiates signaling | Upstream activator of IL-1 beta transcription |
| MYD88 | Adapter in TLR signaling | Required for LPS-induced IL-1 beta production |
| NLRP1 | Another inflammasome sensor | Can activate caspase-1 in response to specific triggers |
| AIM2 | Inflammasome sensor for DNA | Contributes to caspase-1 activation |
| NLRC4 | Inflammasome sensor for bacterial flagellin | Activates caspase-1 |
| IL1R1 | Receptor for IL-1 beta | Mediates feedback and signaling |
| IL1RN | IL-1 receptor antagonist | Negative regulator of IL-1 signaling |
| SIRT1 | Deacetylase that can suppress inflammation | Potential negative regulator of IL-1 beta |
| PPARG | Nuclear receptor with anti-inflammatory effects | Modulates IL-1 beta production |
How Is regulation of interleukin-1 beta production Regulated?
The regulation of IL-1 beta production is itself subject to multiple layers of control. At the transcriptional level, NF-kB and MAPK pathways are activated by pattern recognition receptors such as TLR4. Post-transcriptional mechanisms, including mRNA stability and microRNA targeting, also play roles. Inflammasome activation is controlled by ion fluxes, lysosomal damage, and reactive oxygen species. Negative feedback loops involve IL-1 receptor antagonist (IL1RN) and anti-inflammatory cytokines like IL-10. Additionally, metabolic signals such as hyperglycemia can impair IL-1 beta production, as seen in type 2 diabetes. These regulatory mechanisms ensure that IL-1 beta is produced appropriately and transiently.
regulation of interleukin-1 beta production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NLRP3 | Cryopyrin-associated periodic syndromes | Knock-in mice with NLRP3 mutations; THP-1 cells |
| IL1B | Autoinflammatory diseases, diabetes | IL1B knockout mice; overexpression in cell lines |
| CASP1 | Inflammasome-related disorders | CASP1 knockout macrophages |
| ADAM17 | Alzheimer's disease (via APP processing) | Neuronal cultures with ADAM17 knockdown |
| IL1RN | DIRA (deficiency of IL-1 receptor antagonist) | IL1RN knockout mice |
Autoinflammatory Diseases
Mutations in inflammasome components such as NLRP3 lead to excessive IL-1 beta production and cryopyrin-associated periodic syndromes. Anti-IL-1 beta therapies are effective in these conditions. Understanding GO:0032651 is therefore directly relevant to diagnosing and treating autoinflammatory diseases.
Type 2 Diabetes Mellitus
Patients with type 2 diabetes mellitus exhibit defective production of IL-1 beta, which can be restored by proper glycemic control. This suggests that chronic hyperglycemia impairs certain immune functions, and modulating IL-1 beta production may have therapeutic implications.
Cystic Fibrosis
In cystic fibrosis, IL-1 beta is a potential mediator of airway nitric oxide deficiency, contributing to inflammation and lung damage. Targeting IL-1 beta production could help manage airway inflammation in these patients.
Neurodegeneration
IL-1 beta upregulates TACE in neurons, enhancing alpha-cleavage of APP and decreasing Abeta production. This links IL-1 beta regulation to Alzheimer's disease pathology, where neuroinflammation is a key feature.
From regulation of interleukin-1 beta production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate IL-1 beta production? | CRISPR knockout in THP-1 or RAW264.7 cells followed by LPS/ATP stimulation |
| Does a point mutation in NLRP3 affect IL-1 beta release? | Knock-in of mutant NLRP3 in iPSC-derived macrophages |
| Can overexpression of a candidate gene enhance IL-1 beta production? | Lentiviral overexpression in primary monocytes |
| What is the role of a specific phosphorylation site in caspase-1? | Point mutation knock-in in cell lines |
| How does a disease-associated SNP affect IL1B transcription? | Reporter assays with CRISPR knock-in of SNP |
| Can we screen for regulators of IL-1 beta production? | CRISPR library screening in THP-1 reporter cells |
How to Study the regulation of interleukin-1 beta production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | Secreted IL-1 beta protein | Quantifying production in cell culture supernatants |
| Western blot | Pro- and mature IL-1 beta in lysates | Assessing cleavage and expression |
| qRT-PCR | IL1B mRNA levels | Measuring transcriptional regulation |
| CRISPR knockout | Gene function loss | Identifying essential regulators |
| CRISPR activation (CRISPRa) | Gene overexpression | Screening for enhancers of IL-1 beta |
| Flow cytometry | Intracellular IL-1 beta | Single-cell analysis of production |
| Multiplex cytokine assay | Multiple cytokines including IL-1 beta | Profiling inflammatory responses |
| Inflammasome activation assays | Caspase-1 activity, speck formation | Studying inflammasome-dependent production |
ELISA and Cytokine Bead Arrays
Quantification of secreted IL-1 beta in culture supernatants is the gold standard for measuring production. ELISA and multiplex bead arrays allow sensitive detection of IL-1 beta and other cytokines, as used in studies of rebamipide and apigenin.
Western Blot and Immunoprecipitation
Western blotting can detect pro-IL-1 beta and mature IL-1 beta in cell lysates, distinguishing between synthesis and cleavage. Immunoprecipitation can identify interacting partners. These methods were employed to study TACE upregulation by IL-1 beta.
RNA Interference and CRISPR Screens
Loss-of-function studies using siRNA or CRISPR knockout are powerful for identifying genes that regulate IL-1 beta production. High-throughput CRISPR screens can uncover novel regulators in an unbiased manner.
Reporter Assays and Imaging
Luciferase reporters driven by the IL1B promoter or NF-kB response elements can measure transcriptional activation. Fluorescence microscopy can visualize inflammasome speck formation and IL-1 beta localization.
How CRISPR Can Be Used to Study GO:0032651 regulation of interleukin-1 beta production
Knockout
CRISPR knockout of candidate genes such as NLRP3, CASP1, or IL1B in cell lines like THP-1 or RAW264.7 can definitively test their requirement for IL-1 beta production. For example, CASP1 knockout abolishes monosodium urate crystal-induced IL-1 beta production.
Point Mutation
Introducing precise point mutations (e.g., in NLRP3 or IL1B) using CRISPR base editing or HDR can model disease-associated variants and dissect signaling domains. This is particularly useful for studying autoinflammatory mutations.
Knock-in
Knock-in of reporter genes (e.g., luciferase or fluorescent proteins) into the IL1B locus allows real-time monitoring of IL-1 beta production. Knock-in of epitope tags facilitates protein purification and interaction studies.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can drive supraphysiological expression of candidate regulators to test sufficiency. This approach can identify genes that enhance IL-1 beta production when overexpressed.
How EDITGENE Supports regulation of interleukin-1 beta production Research
Researchers studying regulation of interleukin-1 beta production-related genes often need to determine whether a candidate gene is causally involved in the process or merely correlated. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such causal studies, from knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for regulation of interleukin-1 beta production research.
Frequently Asked Questions About regulation of interleukin-1 beta production
What is GO:0032651?
GO:0032651 is the Gene Ontology term for regulation of interleukin-1 beta production, defined as any process that modulates the frequency, rate, or extent of IL-1 beta production, including biosynthesis and secretion.
What genes are involved in regulation of interleukin-1 beta production?
Key genes include IL1B, NLRP3, CASP1, ADAM17, NFKB1, and IL6, among others. These genes control transcription, inflammasome activation, and secretion of IL-1 beta.
How is IL-1 beta production regulated?
IL-1 beta production is regulated at multiple levels: transcription (e.g., NF-kB), inflammasome activation (NLRP3, caspase-1), oxidative stress, and secretion mechanisms.
What diseases are associated with dysregulated IL-1 beta production?
Autoinflammatory diseases, type 2 diabetes, cystic fibrosis, osteoarthritis, and neuroinflammatory conditions such as Alzheimer's disease.
What cell models are used to study IL-1 beta production?
Common models include THP-1, RAW264.7, primary monocytes/macrophages, and human lymphocytes. These cells respond to stimuli like LPS and monosodium urate crystals.
How can CRISPR be used to study regulation of IL-1 beta production?
CRISPR knockout, knock-in, point mutation, and overexpression can test the causal role of specific genes in IL-1 beta production. For example, CASP1 knockout blocks crystal-induced IL-1 beta.
What is the role of caspase-1 in IL-1 beta production?
Caspase-1 cleaves pro-IL-1 beta into its active form. Its activation is a key regulatory step, often downstream of inflammasome assembly.
Can IL-1 beta production be measured in cell culture supernatants?
Yes, ELISA and multiplex cytokine assays are commonly used to quantify secreted IL-1 beta in supernatants.
What is the link between IL-1 beta and TACE?
IL-1 beta upregulates TACE (ADAM17) in neurons, which enhances alpha-cleavage of APP and decreases Abeta production, linking inflammation to Alzheimer's disease.
How does type 2 diabetes affect IL-1 beta production?
Patients with type 2 diabetes mellitus show defective IL-1 beta production, which can be restored by proper glycemic control.
Conclusion
Regulation of interleukin-1 beta production (GO:0032651) is a fundamental biological process with broad implications for health and disease. From inflammasome activation to cytokine feedback, multiple layers of control ensure appropriate IL-1 beta levels. Dysregulation contributes to autoinflammatory, metabolic, and neurodegenerative disorders, making this process a prime target for therapeutic intervention. Continued research using advanced CRISPR models and screening technologies will further unravel its complexities and identify new drug targets.
References
- 1. Zhang S et al.. 2019. MSC exosomes alleviate temporomandibular joint osteoarthritis by attenuating inflammation and restoring matrix homeostasis.. Biomaterials 200:35-47 PMID: 30771585
- 2. Park CH et al.. 2020. Effects of Apigenin on RBL-2H3, RAW264.7, and HaCaT Cells: Anti-Allergic, Anti-Inflammatory, and Skin-Protective Activities.. Int J Mol Sci 21(13) PMID: 32610574
- 3. Kousathana F et al.. 2017. Defective production of interleukin-1 beta in patients with type 2 diabetes mellitus: Restoration by proper glycemic control.. Cytokine 90:177-184 PMID: 27918955
- 4. Zhang H. 2011. Anti-IL-1β therapies.. Recent Pat DNA Gene Seq 5(2):126-35 PMID: 21762108
- 5. Nissen G et al.. 2022. Interleukin-1 beta is a potential mediator of airway nitric oxide deficiency in cystic fibrosis.. J Cyst Fibros 21(4):623-625 PMID: 35260353
- 6. Tachida Y et al.. 2008. Interleukin-1 beta up-regulates TACE to enhance alpha-cleavage of APP in neurons: resulting decrease in Abeta production.. J Neurochem 104(5):1387-93 PMID: 18021299
- 7. Brown S et al.. 2018. Synthesis of interleukin 1 beta and interleukin 6 in human lymphocytes is stimulated by tributyltin.. Arch Toxicol 92(8):2573-2586 PMID: 29951691
- 8. Kim SK et al.. 2016. Rebamipide Suppresses Monosodium Urate Crystal-Induced Interleukin-1β Production Through Regulation of Oxidative Stress and Caspase-1 in THP-1 Cells.. Inflammation 39(1):473-482 PMID: 26454448
